Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Innovation and Product Development news
23 July 2026
BioBTX starts construction of PETRA circular aromatics plant
First commercial plant directly converting mixed plastic waste into 10,000 t/yr BTX plus 8,000 t by-products; construction begins early 2027, start-up mid‑2028.
23 July 2026
Johnson & Johnson: TECVAYLI + TALVEY reduce progression risk 89% and death risk 62% in earlier-line RRMM
Phase 3 MonumenTAL-6 shows BCMA+GPRC5D bispecific combo and talquetamab+pomalidomide both significantly improved PFS versus investigator’s choice in patients with 1–4 prior lines.
23 July 2026
Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3
First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.
23 July 2026
EIB study: Europe must boost mineral exploration tenfold to meet CRMA goals
Study finds Europe needs a step-change in exploration spending and permitting reform to convert geological potential into domestic critical raw materials supply.
23 July 2026
KMG‑Aero, KazFoodProducts and KBR advance Kazakhstan SAF project
Two trilateral agreements set out a Process Design Package and a PURESAF ATJ licence to produce SAF from alcohol-based agricultural feedstocks.
22 July 2026
GSK's Jideytro (zidesamtinib) approved in US for ROS1‑positive NSCLC
FDA clears zidesamtinib for adults with advanced ROS1‑positive NSCLC after prior ROS1 inhibitor; ARROS‑1 showed 44% ORR and durable responses, including in brain metastases.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
22 July 2026
Takeda’s ORZEYFUL (oveporexton) approved in China as first OX2R agonist for narcolepsy type 1
China approves first oral OX2R-selective orexin agonist for narcolepsy type 1 for patients 16 and older; Phase 3 trials reported improvements in sleepiness and cataplexy.
22 July 2026
Timphaus farm adds EnviTec EnviThan biomethane upgrader in Lohne
Family farm expands biogas plant to produce biomethane; construction began in January with grid injection planned for October.
22 July 2026
Pirelli, Pyrum, Synthos and BASF launch tyre-to-tyre circular supply chain
Converts end-of-life and scrap tyres into recovered carbon black, tyre pyrolysis oil and ISCC PLUS‑certified synthetic rubber for reuse in tyre production.
21 July 2026
CATL and Solarpro sign 2 GWh sodium‑ion storage deal for Eastern Europe
2 GWh sodium‑ion storage agreement aims to deploy next‑gen systems and commission the first sodium‑ion energy storage project in Central and Eastern Europe.
21 July 2026
SABIC and CEER sign MoU to explore materials collaboration for Saudi EVs
MoU to assess advanced materials for EV applications, co-develop material and processing solutions, share sustainability know‑how and support a local supply chain for the Saudi EV sector.
21 July 2026
Gilead & Merck: Once-weekly islatravir/lenacapavir (ISL/LEN) maintained viral suppression in Phase 3 ISLEND trials
Phase 3 ISLEND-1/2 show once-weekly oral ISL/LEN noninferior to daily regimens at Week 48 with low discontinuations and similar safety profiles.
21 July 2026
PTT Global Chemical wins BRIPC Best Practice Case in IP 2025 for muconic acid patent
Patent for improved muconic acid commercialized; collaboration with Toray advanced bio-based adipic acid and pre-commercial Bio‑Nylon 6,6, supporting circular economy.
21 July 2026
Evonik and Celtic Renewables partner to make ECOHANCE Soft BOL from bio-butanol
Waste-derived bio-butanol is being used to produce a low-carbon cosmetic emollient; firms say switching to bio-based ingredients can cut product emissions by up to 60% and more uses are being explored.
20 July 2026
Moeve Chemicals completes global verification for Low Carbon production
All production plants verified to supply Low Carbon products, enabling global customers to access verified, traceable lower‑carbon LAB and phenol alternatives.
20 July 2026
WuXi Biologics hits 1,000th molecule milestone with Earendil Labs trispecific antibody
Trispecific ophthalmic antibody marks the platform's 1,000th molecule; collaboration advanced multiple multispecifics, fusion proteins and ADCs from DNA to IND with faster-than-average timelines.
20 July 2026
Coolbrook and ABB advance RotoDynamic Heater to industrial delivery for Adani Cement
Industrial-scale RotoDynamic Heater installation at Boyareddypalli cement plant; electrical equipment, drives and DCS supplied by partner; expected ~60,000 tCO2 reduction annually.
20 July 2026
GSK Bexsero: EMA accepts submission to add single-dose booster for 10+ years
Phase 3b data indicate a single Bexsero booster at age 10+ boosts immunity in those primed in infancy; full study results will be presented at IPNC in September.
17 July 2026
SONATRACH and Siemens Energy sign MoU on maintenance, green hydrogen and compression
MoU to co-develop maintenance and repair solutions, training, digitalisation and predictive maintenance, and to support local green steel and green ammonia value chains.
17 July 2026
European Commission Electrification Action Plan and ETS review
Sets a 46% electrification target by 2040, reforms the EU ETS to drive investment and stability, and mobilises funding and regulatory measures to lower electricity costs and speed grid rollout.
17 July 2026
GSK updates CALM-1 and CALM-2 camlipixant phase III results
50 mg twice daily cut 24‑hour coughs in CALM‑1; CALM‑2 and the 25 mg dose failed primary/secondary endpoints, prompting halt of RCC development.
16 July 2026
Alfen and CATL partner on 5 GWh sodium‑ion storage deployment in Europe
Joint plan to deploy 5 GWh of sodium‑ion battery storage across Europe to cut costs, diversify supply and reduce exposure to lithium price swings.
16 July 2026
Takeda: Zasocitinib achieves high, consistent clearance at hard-to-treat psoriasis sites
Phase 3 secondary data show ~75% scalp and ~70% palmoplantar clearance at week 16; significant nail improvement; responses sustained to week 24; common AEs: URTI, nasopharyngitis, acne.
16 July 2026
Eastman’s Kingsport methanolysis plant hosts EPA officials
EPA leaders toured a methanolysis unit that processes >250 million lb/yr of polyester waste and reports 20–30% lower GHGs versus fossil-based plastic production.
16 July 2026
Infinium supplies eNaphtha for On's CleanCloud EVA midsole
CO₂‑derived eNaphtha used as a drop‑in feedstock to produce EVA midsoles at commercial scale; shipments began in 2024, ISCC PLUS chain‑of‑custody, and more than one million pairs produced.
16 July 2026
Lilly to acquire AtaiBeckley to add rapid-acting neuroplastogen pipeline
Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.
16 July 2026
Merck’s LIPFENDRA — first FDA‑approved once‑daily oral PCSK9 inhibitor
Oral macrocyclic peptide enlicitide (20 mg) lowers LDL-C ~56–59% at week 24 in Phase 3 trials; approved as adjunct to diet and exercise for adults with hypercholesterolemia, including HeFH.
16 July 2026
Air Liquide invests >160M USD in Arizona for ultra‑pure gases for advanced chips
Arizona plant to supply ultra-high-purity gases for advanced-chip fab expansion using on-site low-carbon hydrogen production and CO2 capture.
15 July 2026
Repsol, Toyota, BMW and Bosch pilot cars on 100% renewable gasoline
Six-month Spanish trial uses existing cars, 100% renewable gasoline and digital tracking to demonstrate drop-in fuel scalability without new vehicles or infrastructure.
15 July 2026
Novo Nordisk wins EU authorisation for Wegovy pill and single‑dose 7.2 mg pen
OASIS data showed ~17% mean weight loss and ~1 in 3 reached ≥20%; safety comparable to injectable semaglutide; wider roll‑out planned in H2 2026.
Next →
